Zai Lab Ltd. logo

Zai Lab Ltd. (ZLAB)

Market Closed
3 Jul, 20:00
NASDAQ (NMS) NASDAQ (NMS)
$
36. 40
+0.91
+2.56%
$
3.83B Market Cap
- P/E Ratio
0% Div Yield
582,000 Volume
-3.45 Eps
$ 35.49
Previous Close
Day Range
36.1 36.97
Year Range
16.01 44.34
Want to track ZLAB and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 37 days

Summary

ZLAB closed yesterday higher at $36.4, an increase of 2.56% from Wednesday's close, completing a monthly increase of 21.33% or $6.4. Over the past 12 months, ZLAB stock gained 43.31%.
ZLAB is not paying dividends to its shareholders.
The last earnings report, released on May 06, 2025, exceeded the consensus estimates by 0.1%. On average, the company has surpassed earnings expectations by 0.1%, based on the last three reports. The next scheduled earnings report is due on Aug 11, 2025.
The stock of the company had never split.
The company's stock is traded on 7 different exchanges and in various currencies, with the primary listing on NASDAQ (NMS) (USD).

ZLAB Chart

Chart

Chart with 60 data points.
The chart has 1 X axis displaying categories.
The chart has 2 Y axes displaying values, and values.
End of interactive chart.
Zai Lab Limited Is Well Positioned For Long-Term Growth

Zai Lab Limited Is Well Positioned For Long-Term Growth

Zai Lab leverages partnerships and regulatory expertise to commercialize innovative drugs in China, reducing trial risks and accelerating market entry. A robust pipeline with multiple anticipated product launches each year, driving strong revenue growth toward a $1.5–$2 billion target by 2028. The company's strong balance sheet and diverse product portfolio minimize risk.

Seekingalpha | 1 month ago
Zai Lab Limited (ZLAB) Q1 2025 Earnings Call Transcript

Zai Lab Limited (ZLAB) Q1 2025 Earnings Call Transcript

Zai Lab Limited (NASDAQ:ZLAB ) Q1 2025 Earnings Conference Call May 8, 2025 8:00 AM ET Company Participants Christine Chiou - Senior Vice President, Investor Relations Samantha Du - Founder, Chairperson and Chief Executive Officer Josh Smiley - President and Chief Operating Officer Rafael Amado - President, Head of Global Research and Development Yajing Chen - Chief Financial Officer Jonathan Wang - Chief Business Officer Conference Call Participants Michael Yee - Jefferies Louise Chen - Scotiabank Yen-Der Li - Leerink Partners Li Watsek - Cantor Yigal Nochomovitz - Citi Anupam Rama - JPMorgan Jack Lin - Morgan Stanley Rebecca Liang - Bernstein Linhai Zhao - Goldman Sachs Operator Hello, ladies and gentlemen, thank you for standing by, and welcome to Zai Lab's First Quarter 2025 Financial Results Conference Call. At this time, all participants are in listen-only mode.

Seekingalpha | 1 month ago
Zai Lab Limited (ZLAB) Reports Q1 Earnings: What Key Metrics Have to Say

Zai Lab Limited (ZLAB) Reports Q1 Earnings: What Key Metrics Have to Say

Although the revenue and EPS for Zai Lab Limited (ZLAB) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks | 1 month ago

Zai Lab Ltd. Dividends

ZLAB is not paying dividends to its shareholders.

Zai Lab Ltd. Earnings

11 Aug 2025 (In 1 month) Date
-
Cons. EPS
-
EPS
6 May 2025 Date
-
Cons. EPS
-
EPS
25 Feb 2025 Date
-
Cons. EPS
-
EPS
12 Nov 2024 Date
-
Cons. EPS
-
EPS
5 Nov 2024 Date
-
Cons. EPS
-
EPS
ZLAB is not paying dividends to its shareholders.
11 Aug 2025 (In 1 month) Date
-
Cons. EPS
-
EPS
6 May 2025 Date
-
Cons. EPS
-
EPS
25 Feb 2025 Date
-
Cons. EPS
-
EPS
12 Nov 2024 Date
-
Cons. EPS
-
EPS
5 Nov 2024 Date
-
Cons. EPS
-
EPS

Zai Lab Ltd. (ZLAB) FAQ

What is the stock price today?

The current price is $36.40.

On which exchange is it traded?

Zai Lab Ltd. is listed on NASDAQ (NMS).

What is its stock symbol?

The ticker symbol is ZLAB.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 0%.

What is its market cap?

As of today, the market cap is 3.83B.

When is the next earnings date?

The next earnings report will release on Aug 11, 2025.

Has Zai Lab Ltd. ever had a stock split?

No, there has never been a stock split.

Zai Lab Ltd. Profile

Biotechnology Industry
Healthcare Sector
Ying Du CEO
NASDAQ (NMS) Exchange
98887Q104 Cusip
CN Country
1,869 Employees
- Last Dividend
- Last Split
20 Sep 2017 IPO Date

Overview

Zai Lab Limited is a biopharmaceutical company founded in 2013, dedicated to discovering, developing, and commercializing a broad range of therapies. The company focuses on treating a variety of conditions including oncology, autoimmune disorders, infectious diseases, and neuroscience disorders. Headquartered in Shanghai, China, Zai Lab has established multiple license and collaboration agreements with leading pharmaceutical companies worldwide to expand its product portfolio and research capabilities. These collaborations enable the company to leverage revolutionary technologies and compounds to address unmet medical needs in various therapeutic areas.

Products and Services

Zai Lab Limited's product pipeline includes:

  • Zejula: An orally administered poly polymerase 1/2 inhibitor used for treating cancer.
  • Optune: A novel cancer therapy utilizing electric fields tuned to specific frequencies aimed at disrupting the growth of tumor cells.
  • NUZYRA: A treatment option for acute bacterial skin and skin structure infections, as well as community-acquired bacterial pneumonia.
  • Qinlock: Designed for the treatment of gastrointestinal stromal tumors.
  • VYVGART: A human IgG1 antibody fragment targeting myasthenia gravis.
  • Tumor Treating Fields (TTFields): A portable device that delivers electric fields for treating tumors, developed in collaboration with NovoCure.
  • Repotrectinib: A tyrosine kinase inhibitor targeting ROS1 and TRK A/B/C in cancer patients, under development in collaboration with BMS.
  • Tisotumab vedotin: An antibody-drug conjugate for cancer treatment, developed in partnership with BMS.
  • Adagrasib: A compound targeting KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer, developed in collaboration with Mirati.
  • Bemarituzumab: Focused on treating gastric and gastroesophageal junction cancer patients, in partnership with Amgen.
  • Sulbactam/Durlobactam: A combination therapy for serious infections caused by Acinetobacter, developed in collaboration with Innoviva.
  • KarXT: Aimed at treating psychiatric and neurological conditions, under development in collaboration with Karuna.

In addition to these products, Zai Lab actively engages in research and development through collaborations with companies such as Tesaro, Inc., Deciphera, Paratek Bermuda Ltd., and argenx to enrich its pipeline and enhance treatment options available to patients worldwide.

Contact Information

Address: Jinchuang Plaza
Phone: 86 21 6163 2588